Novel adjuvants and vaccine delivery systems
Identifieur interne : 000622 ( Istex/Curation ); précédent : 000621; suivant : 000623Novel adjuvants and vaccine delivery systems
Auteurs : Bror Morein [Suède] ; María Villacrés-Eriksson [Suède] ; Anders Sjölander [Suède] ; Karin Lövgren Bengtsson [Suède]Source :
- Veterinary Immunology and Immunopathology [ 0165-2427 ] ; 1996.
English descriptors
- Teeft :
- Adjuvant, Adjuvant activity, Allergy appl, Aluminium hydroxide, Antibody formation, Benner, Boca raton, Bone marrow, Cell culture work, Cell response, Cell responses, Complete adjuvant, Cytokine, Delivery systems, Dendritic cells, Depot effect, Dextran sulphate, Digestive tract, High doses, Hydroxide, Immune, Immune response, Immune responses, Immunization, Immunol, Immunology, Important task, Influenza, Influenza virus, Influenza virus envelope, Influenza virus iscoms, Iscom, Iscom matrix, Iscoms, Liposome, Long period, Lovgren bengtsson, Lymph, Lymph nodes, Lymphatic system, Macrophage, Memory cells, Microspheres, Morein, Mucosal, Node, Novel delivery systems, Oral vaccines, Particulate form, Proliferative response, Respiratory tract, Spherical particles, Spleen, Subunit, Unpublished data, Vaccine.
Abstract
Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.
Url:
DOI: 10.1016/S0165-2427(96)05697-8
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000655
Links to Exploration step
ISTEX:E36E830A8DEA0E8E1025E05505689770D30009C4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Novel adjuvants and vaccine delivery systems</title><author><name sortKey="Morein, Bror" sort="Morein, Bror" uniqKey="Morein B" first="Bror" last="Morein">Bror Morein</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Villacres Eriksson, Maria" sort="Villacres Eriksson, Maria" uniqKey="Villacres Eriksson M" first="María" last="Villacrés-Eriksson">María Villacrés-Eriksson</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Sjolander, Anders" sort="Sjolander, Anders" uniqKey="Sjolander A" first="Anders" last="Sjölander">Anders Sjölander</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Lovgren Bengtsson, Karin" sort="Lovgren Bengtsson, Karin" uniqKey="Lovgren Bengtsson K" first="Karin" last="Lövgren Bengtsson">Karin Lövgren Bengtsson</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E36E830A8DEA0E8E1025E05505689770D30009C4</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0165-2427(96)05697-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000655</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000655</idno><idno type="wicri:Area/Istex/Curation">000622</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Novel adjuvants and vaccine delivery systems</title><author><name sortKey="Morein, Bror" sort="Morein, Bror" uniqKey="Morein B" first="Bror" last="Morein">Bror Morein</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Villacres Eriksson, Maria" sort="Villacres Eriksson, Maria" uniqKey="Villacres Eriksson M" first="María" last="Villacrés-Eriksson">María Villacrés-Eriksson</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Sjolander, Anders" sort="Sjolander, Anders" uniqKey="Sjolander A" first="Anders" last="Sjölander">Anders Sjölander</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Lovgren Bengtsson, Karin" sort="Lovgren Bengtsson, Karin" uniqKey="Lovgren Bengtsson K" first="Karin" last="Lövgren Bengtsson">Karin Lövgren Bengtsson</name><affiliation wicri:level="1"><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Veterinary Immunology and Immunopathology</title><title level="j" type="abbrev">VETIMM</title><idno type="ISSN">0165-2427</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">54</biblScope><biblScope unit="issue">1–4</biblScope><biblScope unit="page" from="373">373</biblScope><biblScope unit="page" to="384">384</biblScope></imprint><idno type="ISSN">0165-2427</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0165-2427</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Adjuvant activity</term><term>Allergy appl</term><term>Aluminium hydroxide</term><term>Antibody formation</term><term>Benner</term><term>Boca raton</term><term>Bone marrow</term><term>Cell culture work</term><term>Cell response</term><term>Cell responses</term><term>Complete adjuvant</term><term>Cytokine</term><term>Delivery systems</term><term>Dendritic cells</term><term>Depot effect</term><term>Dextran sulphate</term><term>Digestive tract</term><term>High doses</term><term>Hydroxide</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunization</term><term>Immunol</term><term>Immunology</term><term>Important task</term><term>Influenza</term><term>Influenza virus</term><term>Influenza virus envelope</term><term>Influenza virus iscoms</term><term>Iscom</term><term>Iscom matrix</term><term>Iscoms</term><term>Liposome</term><term>Long period</term><term>Lovgren bengtsson</term><term>Lymph</term><term>Lymph nodes</term><term>Lymphatic system</term><term>Macrophage</term><term>Memory cells</term><term>Microspheres</term><term>Morein</term><term>Mucosal</term><term>Node</term><term>Novel delivery systems</term><term>Oral vaccines</term><term>Particulate form</term><term>Proliferative response</term><term>Respiratory tract</term><term>Spherical particles</term><term>Spleen</term><term>Subunit</term><term>Unpublished data</term><term>Vaccine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000622 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000622 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:E36E830A8DEA0E8E1025E05505689770D30009C4
|texte= Novel adjuvants and vaccine delivery systems
}}
| This area was generated with Dilib version V0.6.33. |  |